Syndrome de Stevens-Johnson et aggravation d’un lupus systémique induits par la terbinafine

Terrab, Z.; Ouazzani, T. El; Zouhair, K.; Kabli, H. El; Lakhdar, H.

doi:10.1016/s0151-9638(06)70941-3

Cited by 13 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3] Numerous case reports have surfaced highlighting occurrence of SJS in patients with SLE. [78] This could probably be attributed to underlying immune mechanisms which remain unexplored yet. In our case, coexistence of both the possibilities led to diagnostic dilemma.…”

Section: Discussionmentioning

confidence: 99%

First case of mirtazepine-induced Stevens-Johnson syndrome from India

et al. 2012

View full text Add to dashboard Cite

A 28-year-old woman, a known case of systemic lupus erythematosus (SLE), was admitted with mucocutaneous ulceroerosive lesions with blisters and thrombocytopenia after taking antidepressant mirtazepine. Exacerbation of SLE and drug-induced eruption was diagnosed. Clinical and laboratory markers were suggestive of Stevens-Johnson syndrome. This is a rare adverse effect of the newer generation antidepressant mirtazepine.

show abstract

Section: Discussionmentioning

confidence: 99%

First case of mirtazepine-induced Stevens-Johnson syndrome from India

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In all three, along with positive ANA, patients also had antibodies to Ro/SS-A and/or La/SS-B, as is characteristic in SCLE. Including the patient described here, there are currently (as of April 2008) 28 reports in the English, French, and German literature of terbinafine-induced LE ( Table 1; [4][5][6][7][8][9][10][11][12][13][14][15]). In one patient, there was concomitant onset of Stevens-Johnson syndrome [13]; in all patients, the skin lesions and/or documented antibody status are compatible with the presence of SCLE.…”

Section: Discussionmentioning

confidence: 99%

Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature

Lorentz

Booken

Goerdt

et al. 2008

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Systemic lupus erythematosus and subacute cutaneous lupus erythematosus (SCLE) occasionally evolve as adverse reactions to a large variety of chemically different drugs. We here report on a 76-year-old woman who developed SCLE within 10 days after initiation of oral terbinafine. Analysis of the 27 cases of terbinafine-induced SCLE in the literature revealed that this disorder has been reported 6 times more often in females than in males. Skin lesions evolved on average around 7 weeks after starting the drug. In 79% of the cases ANA could be detected while antibodies against Ro/SS-A and La/SS-B were found in 86% and 39%, respectively. Remarkably, anti-histone antibodies were present in only 29%. In all cases terbinafine-induced SCLE resolved after discontinuation of the triggering agent. Systemic treatment with anti-malarials and/or corticosteroids does not appear to be mandatory.

show abstract

“…It can be difficult to distinguish SJS/TEN from the TEN variant of lupus. Patients with lupus may have SJS/TEN in isolation, drug-induced SJS/TEN with “concomitant aggravation of lupus erythematosus,” or the TEN variant of lupus [ 26 ]. When attempting to differentiate etiologies, a careful history with attention paid to offending drug agents is paramount.…”

Section: Cutaneous Manifestations Of Lupusmentioning

confidence: 99%

Cutaneous Manifestations of “Lupus”: Systemic Lupus Erythematosus and Beyond

Cooper

Pisano

Shapiro

2021

International Journal of Rheumatology

View full text Add to dashboard Cite

Lupus, Latin for “wolf,” is a term used to describe many dermatologic conditions, some of which are related to underlying systemic lupus erythematosus, while others are distinct disease processes. Cutaneous lupus erythematosus includes a wide array of visible skin manifestations and can progress to systemic lupus erythematosus in some cases. Cutaneous lupus can be subdivided into three main categories: acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, and chronic cutaneous lupus erythematosus. Physical exam, laboratory studies, and histopathology enable differentiation of cutaneous lupus subtypes. This differentiation is paramount as the subtype of cutaneous lupus informs upon treatment, disease monitoring, and prognostication. This review outlines the different cutaneous manifestations of lupus erythematosus and provides an update on both topical and systemic treatment options for these patients. Other conditions that utilize the term “lupus” but are not cutaneous lupus erythematosus are also discussed.

show abstract

Syndrome de Stevens-Johnson et aggravation d’un lupus systémique induits par la terbinafine

Cited by 13 publications

References 14 publications

First case of mirtazepine-induced Stevens-Johnson syndrome from India

First case of mirtazepine-induced Stevens-Johnson syndrome from India

Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature

Cutaneous Manifestations of “Lupus”: Systemic Lupus Erythematosus and Beyond

Contact Info

Product

Resources

About